



## **Invitrocue announces Board Changes**

**March 11, 2019** – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Mr Kit Wei Lui as director to replace Ms Jamie Gee Choo Khoo, who is stepping down as director.

Mr. Kit Wei Lui has extensive experience in the equity markets, corporate finance and fund raising. He is the co-founder and director of Harford Vantage Limited, a consulting company specialising in assisting public companies seeking alternative financing and business restructuring. Mr. Lui is also an investor in real estate and hospitality business and holds directorship in HLN Assets Holding Pty Limited and Jtown Hospitality Pty Ltd. Mr. Lui graduated from the University of Newcastle (Australia) with Honours in Bachelor of Engineering (Civil).

**Commenting on the appointment of Mr Lui, Dr. Steven Fang, Executive Chairman, Invitrocue, said:**

*“We are delighted to have Mr Lui as a director of Invitrocue. We look forward to his contributions and guidance on the equity market. We would also like to thank Ms Jamie Khoo for her contributions and wishes her all the best in her future endeavours.”*

**-END-**

**For more information contact:**

Martin D. Bach, VP Operations

T: +65 6460 0497

[martind.bach@invitrocue.com](mailto:martind.bach@invitrocue.com)

**About Invitrocue**

Invitrocue is a leading healthcare bio-analytic solutions provider including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. Invitrocue’s Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).

Invitrocue’s technology originated in Singapore’s Agency for Science, Technology and Research (A\*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.

Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ. Website: [www.invitrocue.com](http://www.invitrocue.com)